全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
BMC Cancer  2009 

Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma

DOI: 10.1186/1471-2407-9-270

Full-Text   Cite this paper   Add to My Lib

Abstract:

We measured serum hepcidin-25 levels in 32 patients by liquid chromatograpy (LC)-mass spectrometry (MS)/MS, and assessed hepcidin mRNA expression in paired tumor and non-tumor tissue samples from the surgical specimens of 53 consecutive patients with RCC by real-time reverse transcription polymerase chain reaction.The serum hepcidin-25 level was higher in patients with metastatic RCC than nonmetastatic RCC (P < 0.0001), and was positively correlated with the serum interleukin-6 and C-reactive protein levels (P < 0.001). Expression of hepcidin mRNA was lower in tumor tissues than in non-tumor tissues (P < 0.0001). The serum hepcidin-25 level was not correlated with the expression of hepcidin mRNA in the corresponding tumor tissue specimens from 32 patients. Hepcidin mRNA expression in tumor tissue was correlated with metastatic potential, but not with histological differentiation or tumor stage. Kaplan-Meier analysis showed that over expression of hepcidin mRNA was related to shorter overall survival in RCC patients. Univariate analysis (Cox proportional hazards model) showed that the hepcidin mRNA level was an independent prognostic factor for overall survival.Our findings suggest that a high serum hepcidin-25 level may indicate the progression of RCC, and that upregulation of hepcidin mRNA expression in tumor tissue may be related to increased metastatic potential.Renal cell carcinoma (RCC) is the most common malignant tumor of the kidneys and the third most common malignancy in the urological field. More than 50% of all RCCs are found incidentally, which results in a high percentage of patients with metastasis at the time of diagnosis [1]. In patients with disseminated RCC, conventional chemotherapy, radiotherapy, and immunotherapy have all been tried with limited efficacy [1-4]. Thus, more effective therapy is urgently needed to improve the outcome for patients with advanced RCC. Better understanding of the biology and genetics of RCC have shed light on possible

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133